Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.

Détails

ID Serval
serval:BIB_B149834F3BB7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
Périodique
Journal of Nuclear Medicine
Auteur(s)
Delaloye Angelika Bischof, Antonescu Cristian, Louton Thomas, Kuhlmann Jens, Hagenbeek Anton
ISSN
1535-5667[electronic]
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
50
Numéro
11
Pages
1837-1843
Langue
anglais
Résumé
The objective of this analysis was to assess the radiation exposure associated with (90)Y-ibritumomab tiuxetan when used as consolidation therapy in adults with low or minimal tumor burden after first-line therapy of advanced follicular lymphoma (FL). METHODS: The patients who were enrolled in the phase 3 first-line indolent trial were 18 y or older, with CD20(+) grade 1 or 2 stage III or IV FL, and a partial response, complete response, or unconfirmed complete response to first-line chemotherapy. The patients were allocated randomly to receive a single infusion of unlabeled rituximab 250 mg/m(2) on day -7 and consolidation on day 0 with a single dose of (90)Y-ibritumomab tiuxetan, 14.8 MBq/kg, immediately after unlabeled rituximab, 250 mg/m(2), or no further treatment. On day -7, a subset of patients received an injection of 185 MBq of (111)In-ibritumomab tiuxetan immediately after unlabeled rituximab, 250 mg/m(2), for central dosimetry analysis. Correlations were assessed between organ radiation absorbed dose and toxicity, body weight, body mass index, and progression-free survival. RESULTS: Central dosimetry evaluations were available from 57 of 70 patients. Median radiation absorbed doses were 100 cGy (range, 28-327 cGy) for the red marrow and 72 cGy (range, 46-106 cGy) for the whole body. Radiation absorbed doses did not differ significantly between patients who had a partial response or complete response to initial therapy. Progression-free survival correlated significantly with the whole-body (r = 0.4401; P = 0.0006) and bone marrow (r = 0.2976; P = 0.0246) radiation dose. Body weight was significantly negatively correlated with whole-body radiation dose (r = -0.4971; P < 0.0001). Neither the whole-body radiation dose nor the bone marrow radiation dose correlated with hematologic toxicity. CONCLUSION: In patients with low or minimal residual tumor burden after first-line chemotherapy of advanced FL, whole-body and bone marrow exposure after (90)Y-ibritumomab tiuxetan consolidation showed a significant positive correlation with progression-free survival, whereas dosimetric data could not predict hematologic toxicity.
Mots-clé
Adult, Aged, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal/therapeutic use, Environmental Exposure/adverse effects, Female, Humans, Internationality, Lymphoma, Follicular/drug therapy, Lymphoma, Follicular/pathology, Male, Middle Aged, Neoplasm Staging, Radiation Dosage, Radioimmunotherapy, Radiometry, Treatment Outcome
Pubmed
Web of science
Open Access
Oui
Création de la notice
14/01/2010 13:34
Dernière modification de la notice
20/08/2019 15:20
Données d'usage